Medical device company QT Imaging Holdings Inc (Nasdaq:QTI) announced on Wednesday the launch of the QT Imaging-Olea Viewer, developed in collaboration with Olea Medical, a leader in advanced imaging software solutions.
The viewer provides a unified platform for multiple breast imaging modalities, enabling clinicians to correlate findings across imaging sources and monitor patients longitudinally. It is designed to reduce reliance on multiple software viewers, streamline clinical workflows, and improve efficiency in patient management over time.
QT Imaging's Breast Acoustic CT system uses ultrasound tomography to deliver 3D volumetric breast imaging without ionising radiation or compression, with particular utility in dense breast tissue.
Powered by Olea Medical's visualisation framework, the platform supports advanced 3D rendering, quantitative assessment, and planned AI and machine learning capabilities, including automated lesion segmentation and computer-aided detection.
Product demonstrations will be available at the SBI Breast Imaging Symposium in Seattle.
The collaboration between QT Imaging and Olea Medical, a Canon Medical Systems Corporation company, was announced in January 2026.
Abingdon Health supports UK launch of LVOne stroke triage test
Fesarius Therapeutics reports publication of DermiSphere hDRT data
Shield Therapeutics announces Phase II trial initiation of ACCRUFeR in Japan for PAH
Johnson & Johnson secures EU approval for ETHICON 4000 surgical stapler
Implantica publishes large-scale RefluxStop study showing strong long-term safety outcomes
D2 Solutions acquires ProModRx
Orthocell gains approval for Remplir across US defence and veterans hospital networks
QT Imaging Debuts QT Imaging-Olea Viewer for integrated multimodality breast imaging
MedPal AI launches integrated health OS platform to drive scalable digital healthcare
CenExel appoints Dr. Sy Pretorius as CEO
QT Imaging launches next-generation breast imaging reconstruction software
Tempus and Medtronic report positive ALERT trial results for AI-driven cardiac care
US FDA approves i-Lumen Scientific's i-SIGHT2 clinical study for dry AMD